The acquisition of immortalization is an early and carefully documented event in mouse mammary tumorigenesis. Activation of telomerase activity is one hypothesis to explain the acquisition of immortalization. We examined the activity of telomerase in well-defined immortalized, non-tumor cell populations of mouse mammary tissue in vivo. The results indicated that normal virgin and mid-pregnant mammary gland had low to moderate levels of telomerase activity, respectively. In comparison with the levels detected in pregnant mammary gland, telomerase activity was elevated in mammary tumors in situ and in established mammary cell lines in vitro, both tumorigenic and nontumorigenic; however, hyperplastic alveolar preneoplastic mammary outgrowths and non-tumorigenic ductal outgrowths, both in vivo immortalized populations, had telomerase activity <12% of the levels detected in normal pregnant mammary gland. These results suggest that elevated telomerase activity is not necessary for the immortalization phenotype in in vivo mouse mammary cell populations and that elevated telomerase activity occurs as a late event in mammary tumorigenesis. Furthermore, the data suggest that low levels of telomerase activity are characteristic for mouse mammary epithelial cells and not sufficient for immortalization. These data suggest that other factors play more important roles in the induction and/or maintenance of the immortalization state in mammary cell populations.
Introduction
Most cancers are considered to be immortal cell populations. The telomere hypothesis of cellular immortalization is the favorite hypothesis to explain the acquisition of immortalization (1) (2) (3) (4) . The hypothesis states that telomere size shortens progressively as a consequence of chromosome replication. The end result of telomere shortening is senescence. In order for cancer cells to escape senescence and evolve, the enzyme telomerase is activated and/or increased to stabilize and increase telomere length (2) . This hypothesis is supported by the observation that telomerase is activated in tumor virus induced-immortalization of eukaryotic cells (1, 4) and that numerous established cell lines and tumors of human origin *Abbreviations: EL, extended lifespan; TM, transformed mammary; PBS, phosphate buffered saline; PCNA, polymorphic cell nuclear antigen; CHAPS, 3-([cholamidopragh]-dimethylammonies)-1-propane sulfonate; TRAP, telomeric repeat amplification protocol; PCR, polymerase chain reaction; ITAS, internal telomerase assay standard; TBE, Tris-buffer-EDTA; BrdU, bromodeoxyuridine.
exhibit increased telomerase activity compared with their normal cells (3) . As normal human somatic cells (with some exceptions) exhibit no or extremely low levels of telomerase activity, the results observed in human cell lines and cancer are striking and provide strong support for these hypotheses (3, 5, 6, 7) . In the data by Kim et al. (3) , 98 of 100 immortal human cell populations exhibited positive telomerase activity. This result has been supported and extended by numerous investigators (8) (9) (10) (11) (12) (13) (14) . In contrast, there are a few reports in the literature where specific neoplasias (15) (16) (17) , and immortalized cell lines (18) are not associated with increased telomerase activity. Additionally, telomerase activity has been detected in sun-damaged human skin, skin psoriasis and dermatitis, all nonneoplastic conditions (14) and at low levels in hepatitis (12) .
The status of elevated telomerase activity of human cancers in vivo is consistent among different studies. The status of telomerase activity in pre-malignant human tissues in vivo has not been as thoroughly examined. Data in the literature suggest that pre-malignant lesions of pancreas, prostate, colon (adenomatous polyps), stomach, head and neck (erythroplakia) and benign prostatic hyperplasia do not exhibit elevated telomerase activity (8, 11, 13, (19) (20) (21) . In other experiments premalignant lesions of head and neck, designated as either dysplasia or oral leukoplakia, did exhibit elevated telomerase activity in 100% (7/7) and 38% (10/26) of the lesions, respectively (22, 23) . The mortal or immortalized status of these lesions is unknown. If telomerase function does correlate with immortalization phenotype in human tissues, then one has to conclude that immortalization is a late event in the development of human cancer (2) . However, as stated clearly by others (5, 24) , the data on telomerase activity and immortalization in human tissue is primarily correlative, albeit an extremely strong correlation.
The status of telomerase activity in mouse tumor systems is complicated by the demonstrable levels of telomerase activity in many normal mouse organs (25) (26) (27) . The considerable background levels of telomerase activity in normal mouse organs requires careful quantification of telomerase in tumor cells. Several reports have demonstrated elevated telomerase activity in viral oncogene and carcinogen-induced mouse skin carcinomas (26) (27) (28) , carcinogen-induced rat colon tumors (29) , viral oncogene-induced pancreatic tumors (28) , and mammary tumors from neu transgenic mice (26) . As in human premalignant lesions, elevated telomerase activity was not observed in either pancreatic islet hyperplasia, pre-malignant early stage skin hyperplasia or early stage papillomas, although late stage papillomas did exhibit elevated telomerase activity (26) (27) (28) . It is worth noting that the immortalized status of mouse skin papillomas is not well studied.
In order to critically evaluate the causal relationship between telomerase and immortalization, well-defined immortalized, non-tumorigenic cell populations in vivo are useful. Two recent reports concluded that immortalization of human fibroblasts in vitro could occur in the absence of telomerase activation but with telomere stabilization (30, 31) . In these studies, the criteria of immortalization was an in vitro criteria and not verified by in vivo growth. In vitro cell lines are not optimal models because the lack of in vivo tumorigenicity of these cell lines is not frequently ascertained and also can be due to cultureinduced changes independent of intrinsic tumorigenicity. The mouse mammary system is one of the few models where the acquisition and criteria of immortality in in vivo tissues has been studied and carefully documented (32, 33) . Immortalization has been defined as infinite division potential and is based on orthotopic transplantation of normal or transformed mammary cells into syngeneic mice. The results of such experiments have demonstrated that normal mammary epithelial cells have a finite life span of five to six transplant generations whereas preneoplastic and neoplastic cell poulations can be serially transplanted indefinitely (33, 34) . Recent experiments have demonstrated that the immortalized phenotype can occur independently of hyperplastic or tumorigenic capability (35) . Such in vivo cell populations, termed extended lifespan (EL*), resemble normal mammary ducts morphologically and functionally and are absolutely ovarian hormone dependent for growth and morphogenesis. The p53 status of the EL lines is wild-type (Medina and Butel, unpublished observations).
We have examined the EL ductal outgrowth lines along with established mammary epithelial cell lines in vitro and normal, hyperplastic and neoplastic mammary tissue in vivo for telomerase activity to test the hypothesis that elevated telomerase activity is necessary and sufficient for immortalization.
Materials and methods

Cells and tissues
All cell lines and tissues were of mammary epithelial origin in Balb/c mice. The biological and tumorigenic properties of the cell lines and tissues have been described previously (35) (36) (37) (38) (39) . Briefly, the model system examined herein involves mammary tissues that represent different stages in the development of mammary neoplasia. In this model, normal cells give rise to immortalized ductal outgrowths (termed EL), which are ovarian hormone-dependent and weakly tumorigenic and also to immortalized alveolar outgrowths (termed TM for transformed mammary) which are primarily ovarian hormoneindependent and tumorigenic. The TM outgrowths represent a heterogeneous group of lesions that have been classified into three stages based on their respective tumorigenic potentials. Stage I lesions are non or weakly tumorigenic, stage II lesions have a moderate (20-70%) tumorigenic potential with a long mean latent period for tumor formation (10-12 months) and stage III lesions have a high (Ͼ90%) tumorigenic potential with a short mean tumor latent period (ഛ5 months). The EL and TM cell populations were derived from normal mature virgin mammary gland and arose 'spontaneously' as a consequence of growth in cell culture. Normal mammary tissues were mature virgin gland (12-16, and 56 weeks of age) and mid-pregnant mammary gland (11-14 days). The immortalized ductal lines EL11 and EL12 were from transplant generations 28-37, preneoplastic hyperplastic outgrowth lines TM2L, TM2H, TM3 and TM40 represented hyperplasias from different stages and were from transplant generations 28-33, 37, 22-27 and 9-15 respectively. Tumors were primary tumors arising from the different hyperplasias.
Cell culture
Virgin mammary gland, EL11 and EL12 ductal tissues were also examined before and after primary culture in three-dimensional collagen gels. The epithelial cells were cultured as described previously (36) and examined at day 0 and day 7 of culture in order to examine the telomerase activity in enriched epithelial cells of normal and immortalized mammary ductal cells.
Proliferation assays
BrdU was purchased from Sigma Chemical Co. (St Louis, MO), and was dissolved in sterile phosphate buffered saline (PBS) at 20 mg/ml. Two-hour pulse-labeling experiments were carried out using 4-6 animals per group. Each animal received 70 µg/g body weight bromodeoxyuridine (BrdU) i.p. The animals were killed, mammary glands were harvested, flattened and fixed in methacarn (methanol:chloroform:acetic acid; 60:30:10) overnight and post-2086 fixed in acetone. Paraffin-imbedded tissue samples were cut in 4 µm thick sections, stained with hematoxylin and eosin for general histological study or used for immunohistochemical staining.
Tissue sections were deparaffinized and blocked as described in (40) . BrdU immunohistochemistry was performed using the cell proliferation kit from Amersham following the manufacturer's protocol. The total number of cells counted was 1200 cells per section. For PCNA staining, the procedure was followed as described in (40) .
Telomerase assay
Telomerase was assayed by two versions of the telomeric repeat amplification protocol (TRAP) procedure described initially by Kim et al. (3) with modification of Wright et al. (41) . In our initial studies, each sample was washed with 500 µl of ice-cold wash buffer (10 mM HEPESϪKOH (pH 7.5), 1.5 mM MgCl 2 , 10 mM KCl, 1 mM dithiothreitol) and pelleted at 10 000 r.p.m. for 5 min at 4°C. The washing buffer was removed and 300 µl of ice-cold lysis buffer was added (10 mM TrisϪHCl (pH 7.5), 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM phenyl-methylsulfonyl fluoride, 5 mM β-mercaptoethanol, 0.5% CHAPS, 10% glycerol). The samples were homogenized by hand with a glass grinder and placed on ice for 30 min, and then centrifuged at 16 000 g for 20 min at 4°C. The supernatants were collected into 1.5 ml tubes and flash-frozen in a dry-iceϪethanol bath. Samples were stored at Ϫ80°C. The protein concentration of the cell and tissue extracts were determined with the BCA Protein Assay kit (Pierce) and samples were diluted to a concentration of 1 mg/ml protein.
The telomerase assay was performed in two steps; first, a telomerase extension of an oligonucleotide primer (TS) which served as the substrate for telomerase and second, polymerase chain reaction (PCR) amplification with the oligonucleotide primer pair TS 5Ј-AATCCGTCGAGCAGAGTT-3Ј (forward), and CX5Ј-(CCCTTA)3CCCTAA-3Ј (reverse). The PCR buffer contained 20 mM TrisϪHCl (pH 8.3); 1.5 mM MgCl 2 , 63 mM KCl, 0.005% Tween-20 and 1 mM EGTA. Aliquots of 10 µl of 5XPCR buffer (TRAP buffer) were mixed with 0.1 µg (1 µl) of TS primer, 50 µM each dNTPS (1 µl), bovine serum albumin (0.1 mg/ml), 1 µg of T4g protein (1 µl), 0.4 µl of (α-P32) dCTP (3000 Ci/mmol), 1 µl of a cell extract and 0.5 µl of ITAS DNA (1ϫ10 Ϫ18 g/µl) (added as an internal control). Diethyl pyrocarbonate-treated water was added to bring a total volume of 48.5 µl per assay. The reaction mixture was incubated for 30 min at 22°C for telomerase-mediated extension of the TS primer. Following incubation, 0.1 µg of the CX primer (1 µl) and 2 µl of Taq DNA polymerase (PerkinϪElmer) were added to each tube. The samples were denatured (94°C, 3 min) and subjected to PCR amplification in a thermal cycler for 31 cycles (94°C for 30 s, 50°C for 30 s and 72°C for 45 s). As a positive control, 1 µl of a cell extract from a sample with known telomerase activity (TM-6 mammary tumor cell line) and as a negative control, 1 µl of lysis buffer without cell extract, were used. In addition to the positive and negative samples run in each experiment, experiments assessed the importance of sample size, heat and RNase treatment. Heat and RNase treatment were run on initial experiments using pregnant, virgin and tumor tissue, and, in each case, eliminated telomerase activity. To determine the optimal protein load per sample, for the initial set of assays, pregnant, virgin, EL11 tissue, EL11 and EL12 cultured cells (day 0 and day 7) and TM6 tumor cell line were examined over a range of 0.03 µg to 3 µg. From these experiments, we concluded that 1 µg protein was a reproducible and satisfactory sample size.
In the second set of assays, the same and additional tissue lysates were examined utilizing the TRAPeze TM Telomerase Detection kit (Oncor, Gaithersburg, MD). This kit eliminates the need for a wax barrier hot start and incorporates primers for amplification of a 36-p internal positive standard that provides a positive control for accurate quantitation of telomerase activity with a linear range. Using this kit, we examined a subset of samples over a range of 0.1 µg to 5 µg and picked 2 µg to examine all the samples in two gels run at the same time.
Electrophoresis and quantification
In the initial experiments, the PCR products were analyzed by electrophoresis of 25 µl aliquots of reaction mixtures on 10% non-denaturing, 0.4 mm thick acrylamide gels, run in 0.5ϫTBE buffer until the xylene-cyanol had migrated 15 cm from the bottom of the gel. In the second set of experiments utilizing the TRAPeze TM kit, the samples were electrophoresed on 12% polyacrylamide gels, run in 1ϫTBE buffer until the bromophenal blue marker had migrated 9 cm from the loading wells. The gels were then dried, exposed for 16-20 h to Kodak Biomax film (Eastman Kodak Company). The signal intensity was measured by densitometry. Telomerase activity was determined by adding the intensity of all the bands minus the background observed on the negative control lanes. The signal intensities of the bands from the experimental samples were compared relative to the signal intensity of the bands from the positive controls that were run with each experiment. 
Results
Telomerase activity in normal and neoplastic mammary tissues and in two cell lines in vitro derived from mammary preneoplasias is illustrated in Figure 1 . RNase treatment abolished the activity by 99%. Telomerase activity was present in normal pregnant mammary glands, present weakly in virgin gland (18% of pregnant gland), and at high levels in a TM12 primary mammary tumor (1.7 times greater than pregnant) and in the two preneoplastic cell lines (TM3, TM6; 2.1 times greater than pregnant gland). The 293 human kidney carcinoma cell line was an additional positive control. Levels of telomerase activity in mammary fat pads containing EL11 and EL12 ductal outgrowths gave telomerase activities less than pregnant gland (43% less) and slightly higher than virgin mammary gland.
The epithelial cell compartment of the normal mammary ducts as well as the EL11 and EL12 ductal outgrowths in the mammary fat pad contribute in the order of 10-15% of the total protein mass due to the large contribution of the adipose stroma. In order to rule out the possibility that the low level of telomerase activity was an artifact that reflected the low percentage of ductal epithelial cells, the epithelial component of the mammary gland that contained normal ducts, EL11 and EL12 ductal outgrowths were enriched by enzymatic digestion of the gland and only the epithelial cell pellet was collected. The telomerase activity of the pellets was examined at day of collection (day 0) in three experiments and after 7 days of culture (day 7) in a collagen gel in two of the three experiments. The samples at day 7 of culture represented an increase of epithelial cells caused by active proliferation in the collagen gel with growth factors. Figure 2 illustrates the results of one of these experiments. Telomerase activity was evident in the pregnant mammary gland, it was lower in day-0 virgin epithelial cells (26% of pregnant gland) and day-0 EL11 epithelial cells (18% of pregnant gland), and highest in the TM6 tumor cell line (1.25 times greater than pregnant gland). Culturing the virgin and EL11 ductal outgrowths for 7 days increased the telomerase activity 3.2 times in each case. A repeat of the 7-day culture protocol reproduced the same increase in telomerase activity in both cell populations. The mean telomerase activity of the three zero day experiments for both virgin and EL11 cells was 48% of the pregnant gland. The results demonstrated that telomerase activity was not increased in immortalized, non-tumorigenic mammary epithelial cells.
In order to more carefully quantitate the extent of telomerase activity, we utilized the TRAPeze TM Telomerase Detection kit, which contains an internal standard at 36 bp. Figures 3 and 4 illustrate telomerase activity in normal mammary gland, ductal and alveolar hyperplasias and their derivative tumors. The results show that the cleared mammary fat pad, devoid of epithelia parenchyma, has no detectable activity compared with the low activity in virgin and moderate activity in pregnant gland. The activity in virgin gland was 27% of that in the pregnant gland. Of the six separate ductal and 15 separate hyperplastic outgrowth samples, the mean telomerase activity was 12% of the virgin duct and 12% of the pregnant gland, respectively. The two samples of hyperplasias with modest telomerase activities, were detected in two transplant generations of TM2H and TM3H outgrowths that produced palpable tumors within 4 months after transplantation. In contrast, 15 of 16 tumors exhibited elevated telomerase activity with a mean activity 3.7 times greater than the pregnant gland. The specificity of the assay was confirmed by heat inactivation of telomerase enzyme. Figure 5 shows the titration of the telomerase activity over 0.1 to 5 µg of protein and demonstrates that telomerase activity was not artificially missed or exaggerated in any of the samples. A summary of the relative levels of telomerase activity in the mouse mammary tissues is illustrated in Figure 6 . The results indicate telomerase activity in the immortalized non-tumor populations is ഛ12% of that detected in normal, mortal pregnant mammary gland.
The relationship between proliferation status and telomerase activity is illustrated in Table I . The pregnant mammary gland has significant proliferative activity as measured by BrdU labeling and PCNA-labeling indices. It is of note that the percentage of normal cells (pregnant) that are at some stage in the cell cycle, as reflected by PCNA-labeling, is equal to or greater than the hyperplasias but less than primary tumors. The normal virgin duct and immortalized duct show PCNAlabeling indices 6.2 and 24% respectively (42) . However, the high BrdU-and PCNA-labeling indices and the low telomerase activities of stage II and III hyperplasias suggest there is little direct correlation between the two cellular processes (Table I) .
Discussion
The experiments reported herein examined telomerase activity in a well-characterized model of multistage murine mammary tumorigenesis in vivo. This model is characterized by the presence of discrete and well-defined in vivo cell populations representing four stages in the evolution of normal to neoplastic mammary cells. The experiments specifically addressed the question of whether increased telomerase activity was detectable in immortalized non-tumorigenic mammary ductal cells. The results show that enhanced telomerase activity does not occur in these immortalized cell populations in vivo. To our knowledge, this is the first examination of telomerase activity in a known cell population of immortalized, non-tumorigenic cells in vivo.
The results raise the question of whether this system is the exception to the rule that telomerase activity is necessary and sufficient for cell immortalization. There is extensive data that immortal tumorigenic cell lines in vitro exhibit enhanced telomerase activity (3, 5, 6) . There is also substantial data that immortal, non-tumorigenic cell lines in vitro exhibit telomerase activity. However, the relevance of in vitro cell lines to growth, immortalization and tumorigenicity can be complicated by selection artifacts found in cultured cells. It is not known whether immortalization in vitro measures the same biological phenotype as immortalization in vivo. Establishment of a cell line in vitro essentially selects for a stem cell population grown under the most elemental conditions; i.e. cells in isolation grown in two dimensions under a minimal set of growth factors. However, immortalization of epithelial cells in vivo requires cells to grow in a normal micro-environment in a three-dimensional organization and subject to the influences of neighboring cells and complex hormonal and growth factors. Growth in vivo is thus a more stringent test for immortalization and mimics the event that occurs in the evolution of neoplasia. So far, the only system that in vivo immortalization has been carefully examined in is the mouse mammary system (32) (33) (34) 39) . The mammary system fulfils the requirements to test vigorously the role of telomerase activation in immortalization and tumorigenesis. The current data suggest that increased telomerase activity is not necessary for the immortalization phenotype in mouse mammary cells as demonstrated by the normal levels of telomerase activity in both immortalized, nontumorigenic mammary ductal outgrowths and in immortalized, preneoplastic mammary outgrowths. A second question is whether the low level of telomerase activity present in normal mammary cells is necessary for immortalization. This is a more difficult question to answer by just measuring telomerase activity. Two facts are worth noting. First, the low level of nascent telomerase activity is clearly not sufficient for immortalization as it is well established that virgin and pregnant mammary epithelial cells are mortal cell populations with a life span measured as six transplant generations (32, 33) . The absence of telomerase activity in the cleared fat pads argues that the telomerase activity measured in the gland is of epithelial, not stromal origin. Secondly, it is curious that the level of telomerase activity in the ductal and alveolar outgrowths was actually less than in their respective normal cell controls. This result argues that even the low level of telomerase activity is not maintained or necessary for an immortalized phenotype. The low levels of telomerase activity may reflect other physiological influences on normal cell function such as hormonal regulation of telomerase activity. Recent results have suggested that varying levels of telomerase activity in normal human endometrium and rat prostate reflect hormonal status of the host (43) (44) (45) . In addition, telomerase activity can be downregulated in some types of leukemias exposed to differentiation-inducing agents (46, 47) .
The data reported herein support the emerging data in the literature that telomerase activation in cell population in vivo is a late stage event. Thus, the data in mammary cells is consistent with the results in transgenic mouse models of epidermal carcinogenesis and pancreatic carcinogenesis (28) , and in carcinogen-induced mouse epidermal carcinogenesis (27) . It is also consistent with results published regarding premalignant lesions in human cancer (11, 19, 23) . It is important to note that in none of the above organ systems could the immortalized phenotype be rigorously assessed, therefore the relationship between telomerase activation and immortality could not be directly addressed in these systems.
The data are also consistent with reports in the literature that normal mouse mammary tissues exhibit significant telomerase activity (26, 48) . An apparent discrepancy is the recent report by Broccoli et al. (48) , which reported little telomerase activity in normal virgin gland and wnt-1 hyperplastic mammary glands. The very low levels in normal gland reflect the low epithelial cell component of the virgin mammary gland and are not necessarily a direct measurement of intrinsic telomerase activity in mammary epithelial cells. The low levels in hyperplastic gland are similar to the results reported with the TM hyperplastic lines. The telomerase activity in the TM hyperplasias is 12% of the activity of tumors; this level is similar to the telomerase activity of wnt-1 hyperplasias, which was 14% of telomerase activity in wnt-1 mammary tumors (48) .
The correlation between telomerase activity and the proliferation status of the cells is ambiguous and complex (3, 4, 41, 49) . Some conditions that increase proliferation may also be associated with increase in telomerase activity, but these are distinct from immortalization. Thus, the high levels of telomerase activity in 11 to 14 day pregnant mammary gland may be linked to either the proliferative state of the cells and/or to hormonal stimulation of the gland. Also, the simple process of culturing mammary cells in vitro enhances telomerase activity in normal mammary cells as evidenced herein and by Chadeneau et al. (26) , in immortal mammary cells and established non-tumorigenic cell lines. Alternatively, immortalized cell populations with very low telomerase activities may have proliferation indices that vary from low to high. Thus, proliferation indices of the TM hyperplastic glands are similar to those of the mid-pregnant gland, although they are lower than those observed in tumors. At the other extreme, immortalized ductal outgrowths have very low telomerase activities, with PCNA-labeling indices that are 50% of that found in pregnant gland (38) . With respect to tumors, it is likely that the high level of telomerase activity reflects multiple levels of dysregulation of proliferation controls. This possibility is evidenced in the results of Broccoli et al. (48) who have shown that the levels of telomerase RNA are slightly elevated (two times) in tumors compared with hyperplasias but telomerase activity is elevated eight times. Similarly, the levels of cell-cycle regulatory proteins and their kinase-associated activities are elevated much higher in these mammary tumors than is suggested by an examination of proliferation indices (40) .
It is important to note that the data do not address the question of telomere length as the critical determinant in the acquisition of immortalization. It is conceivable that telomere maintenance in mouse mammary cells is regulated by mechanisms other than the telomerase enzyme. Examples of potential alternative mechanisms have been discussed by Bryan et al. (30) .
In summary, the results demonstrate that elevated telomerase activity is not obligatory for the establishment of the immortalized state in mouse mammary cells in vivo. One has to consider either that the mouse mammary system is an exception to the rule or that telomerase activity reflects altered growth regulation of the tumor cell and is not causal to the acquisition of immortalization. If the latter, attention should be focused on other mechanisms, as emphasized by other investigators (30, 50) . The role of telomerase in chromosomal segregation in mitosis is one example of a different role for telomerase (50) . If the former, then it is necessary to test the telomerase hypothesis of immortalization in carefully defined in vivo systems. Regardless of the answer, it is still important to recognize that telomerase activation is a very frequent event in neoplastic cells of human and murine origin and thus provides an appropriate and inviting target for chemotherapeutic or chemopreventive intervention.
